SIGA Technologies Logo
US8269171067
919473
SIGA

SIGA Technologies

Previsioni

Acquista
  1
Mantieni
  0
Vendi
  0

Discussioni nella community

Non ci sono ancora discussioni su questo asset.

Avvia discussione

  • SIGA Technologies pays special dividend of $0.60 per share

    The board of directors of SIGA Technologies has approved a cash dividend of $0.60 per common share, payable on April 23, 2026 to shareholders of record at the close of trading on April 7, 2026. The payout matches the special dividend announced in April 2025 and, according to InvestingPro, represents a yield of about 12%. The company shows a high liquidity ratio (current ratio 11.83), while the stock, at $4.81, is trading near its 52-week low and has fallen roughly 46% over the past six months. SIGA Technologies is in the commercialization phase and focuses on drugs for the treatment and prevention of infectious diseases, particularly orthopoxviruses. » Altro su de.investing.com


  • SIGA Technologies posts annual profit of $23 million despite quarterly loss

    SIGA Technologies reported 2025 annual revenue of $95 million and a net profit of $23 million, with a cash balance of $155 million and no debt. However, in the fourth quarter the company posted a loss per share of -$0.08, highlighting quarterly volatility due to irregular government procurement. Investor reactions were mixed: the stock fell in after-hours trading but recovered in pre-market trading. Remaining risks include regulatory uncertainty in Europe for the Mpox indication and strong dependence on U.S. government contracts. » Altro su de.investing.com


  • SIGA Technologies reports strong 2025 results and remains debt-free

    SIGA Technologies recorded total revenue of $95 million in 2025, including $88 million in product revenue, and net income of $23 million (earnings per share $0.32). The company holds $155 million in cash, is debt-free, and delivered TPOXX worth $79 million to the U.S. government. Outstanding government orders of $26 million for 2026, plus $27 million in grants for pediatric and intravenous formulations, underpin the optimistic outlook. » Altro su de.investing.com


  • SIGA Technologies: stock falls despite strong revenue growth in third quarter

    SIGA Technologies reported product revenues of $86 million for the first nine months (prior year $54 million), driven by strong TPOXX sales. The company holds $172 million in cash and is debt-free; net income for the nine months amounted to $29 million. The stock fell 3.08% to $8.07 in after-hours trading following the release of the figures. SIGA plans an FDA filing for TPOXX for post-exposure prophylaxis, is working on a pediatric formulation and expects international sales in 2026, but sees risks from procurement delays and regulatory hurdles. » Altro su de.investing.com


  • SIGA Technologies reports stable quarterly results and remains financially solid

    SIGA Technologies posted stable revenues of $79 million and earnings per share of $0.49 in the second quarter of 2025, while the stock price remained nearly unchanged. The company remains debt-free with a cash balance of $182 million and plans to submit new approval applications for its TPOXX products. However, international business development remains volatile, and reliance on US government contracts poses risks. » Altro su de.investing.com

Nel 2026, SIGA Technologies ha già distribuito 0,51 € di dividendi. L'ultimo pagamento è avvenuto a aprile.

Dati finanziari

Nell'ultimo trimestre, SIGA Technologies ha registrato ricavi pari a 1,16 Mln € e un utile netto di -2,55 Mln €

(EUR) settembre 2026
YoY
Ricavi 1,16 Mln 47,92%
Utile lordo 654,46K 52,53%
Utile netto -2,55 Mln 52,91%
EBITDA -4,84 Mln 30,85%

Dati fondamentali

Metrica Valore
Capitalizzazione di mercato
156,84 Mln €
Numero di azioni
71,86 Mln
Massimo/minimo a 52 settimane
6,48 € - 2,16 €
Rendimento da dividendo
19,83%
Dividendi TTM
0,51 €
Beta
1,02
Rapporto P/E
374,22
Rapporto PEG
-3,43
Rapporto P/B
1,05
Rapporto P/S
3,29

Profilo aziendale

SIGA Technologies, Inc., una società farmaceutica in fase commerciale, si concentra sui mercati della sicurezza sanitaria e delle malattie infettive negli Stati Uniti. Il suo prodotto principale è TPOXX, un farmaco antivirale orale per il trattamento del vaiolo umano causato dal virus variola. SIGA Technologies, Inc. ha una partnership strategica con Cipla Therapeutics per garantire un'innovazione sostenuta e l'accesso a farmaci antibatterici, principalmente contro le minacce biologiche. La società è stata costituita nel 1995 e ha sede a New York, New York.

Nome
SIGA Technologies
CEO
Diem Nguyen
Sede centrale New York City, ny
Stati Uniti
Sito web
Settore
Materiali
Industria
Prodotti chimici
Quotazione in borsa
10/09/1997
Dipendenti 49

Simboli di borsa

Borsa Simbolo
NASDAQ
SIGA
🍪

Parqet  usa i cookie. Scopri di più